Video Channel

Alzheimer’s: the search for a cure

One year ago, it looked as though Biogen and Eisai’s aducanumab had joined the long list of failed Alzheimer’s disease drugs. To some people, the setback encountered by aducanumab marked the moment to call time altogether on efforts to treat the disease by targeting amyloid beta.

Full Story